Vanguard FTSE Developed Europe UCITS ETF | VEURRegister to Unlock Ratings |
Performance History | 31/07/2024 |
Growth of 1,000 (GBP) | Advanced Graph |
Fund | 2.9 | 17.4 | -4.9 | 13.8 | 7.6 | |
+/-Cat | -1.4 | 2.1 | 3.4 | 2.2 | 1.6 | |
+/-B’mrk | 0.4 | -0.2 | -0.3 | 0.6 | 0.1 | |
Category: Europe Large-Cap Blend Equity | ||||||
Category Benchmark: Morningstar DM Eur TME NR EUR |
Key Stats | ||
Closing Price 30/08/2024 | EUR 40.69 | |
Day Change | 0.18% | |
Morningstar Category™ | Europe Large-Cap Blend Equity | |
Volume | 5160 | |
Exchange | EURONEXT AMSTERDAM | |
ISIN | IE00B945VV12 | |
Fund Size (Mil) 30/08/2024 | EUR 3950.29 | |
Share Class Size (Mil) 30/08/2024 | EUR 3025.39 | |
Ongoing Charge 17/02/2023 | 0.10% |
Morningstar Research |
Investment Objective: Vanguard FTSE Developed Europe UCITS ETF | VEUR |
This Fund seeks to track the performance of the Index, a widely recognised benchmark a of stock market performance of European developed countries that is comprised of the stocks of large and mid cap sized companies in developed Europe. |
Returns | ||||||||||||||||
|
Management | ||
Manager Name Start Date | ||
Not Disclosed 21/05/2013 | ||
Inception Date 21/05/2013 |
Advertisement |
Category Benchmark | |
Fund Benchmark | Morningstar Benchmark |
FTSE Developed Europe TR EUR | Morningstar DM Eur TME NR EUR |
Target Market | ||||||||||||||||||||
|
Portfolio Profile for Vanguard FTSE Developed Europe UCITS ETF | VEUR | 31/07/2024 |
|
|
Top 5 Holdings | Sector | % |
Novo Nordisk A/S Class B | Healthcare | 3.54 |
ASML Holding NV | Technology | 3.17 |
Nestle SA | Consumer Defensive | 2.32 |
AstraZeneca PLC | Healthcare | 2.08 |
Shell PLC | Energy | 2.04 |
Increase Decrease New since last portfolio | ||
Vanguard FTSE Developed Europe UCITS ETF | VEUR |